Cargando…
Treatment Guidelines for Atopic Dermatitis Since the Approval of Dupilumab: A Systematic Review and Quality Appraisal Using AGREE-II
INTRODUCTION: Since its approval for adults with moderate-to-severe atopic dermatitis (AD) in 2017, dupilumab has been incorporated into clinical practice guidelines (CPGs). However, recommendations differ internationally, and the quality assessment of their development is unclear. OBJECTIVE: We aim...
Autores principales: | Ghazal, Stephanie, Ridha, Zainab, D'Aguanno, Kathleen, Nassim, David, Quaiattini, Andrea, Netchiporouk, Elena, Poulin, Yves, Kalia, Sunil, Marcoux, Danielle, Piguet, Vincent, Jack, Carolyn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959491/ https://www.ncbi.nlm.nih.gov/pubmed/35355606 http://dx.doi.org/10.3389/fmed.2022.821871 |
Ejemplares similares
-
Successful treatment of acrodermatitis continua of Hallopeau with tildrakizumab: A case report
por: Nguyen, Alex, et al.
Publicado: (2023) -
Dupilumab for atopic dermatitis
Publicado: (2019) -
Dupilumab Provides Rapid and Sustained Improvement in SCORing Atopic Dermatitis Outcomes in Paediatric Patients with Atopic Dermatitis
por: WOLLENBERG, Andreas, et al.
Publicado: (2022) -
Severe atopic dermatitis and dupilumab
por: Bernardo, Wanderley, et al.
Publicado: (2023) -
Is Dupilumab as Effective in Intrinsic Atopic Dermatitis as It Is in Extrinsic Atopic Dermatitis?
por: Gelato, Federica, et al.
Publicado: (2023)